Advertisement

Continuing a spring fling of stent approvals, Boston Scientific Corp. today announced that it had won approval from the FDA for its ION drug-eluting coronary stent.

The U.S. Food and Drug Administration has given the OK for Boston Scientific (NYSE: BSX) to sell the ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System that is made using a “unique platinum chromium alloy.” The ION was approved in May 2010 in Europe and other CE Mark countries, where it is known as the TAXUS Element system.

SOURCE

Advertisement
Advertisement